Barclays Reiterates Equal-Weight Rating on Exelixis, Inc. (EXEL)

Market Context

Exelixis, Inc. operates in the Healthcare sector. The stock currently trades at $55.77 with a market capitalization of $11.1B. The stock has gained 24.3% over the past 52 weeks.

Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Exelixis, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Exelixis, Inc.

Among the 10 most recent ratings: 3 Buy, 7 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 14, 2026	Barclays	Equal-Weight	N/A
Jul 13, 2026	Wells Fargo	Equal-Weight	N/A
Jul 07, 2026	Truist Securities	Hold	N/A
Jul 07, 2026	RBC Capital	Sector Perform	N/A
Jul 02, 2026	UBS	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View EXEL Stock Page